Clinical effects of combination of edaravone, clopidogrel and butylphthalide injection on acute progressive cerebral infarction

Objective To analyze the clinical effects of combination of edaravone, clopidogrel and butylphthalide injection in the treatment of acute progressive cerebral infarction. Methods Seventy-eight patients with acute progressive cerebral infarction treated in Shouguang People’s Hospital from August 2018 to July 2019 were selected and divided into two groups, by random number table method. In the control group, 39 patients were treated with clopidogrel tablets and butylphthalide injection; while 39 patients in the observation group were treated with edaravone based on the treatment of control group. The therapeutic effects, neurological function, daily activities ability were compared between the two groups after treatment; and changes of neuron-specific enolase (NES), S-100β protein, interleukin-1, (IL-1) interleukin-2 (IL-2), interleukin-6(IL-6) were analyzed between the two groups. The incidence of adverse reactions of the two groups were observed and recorded. Results After treatment, the American National Institute of Health stroke scale (NIHSS) scores of the observation group were significantly lower than those of the control group, and the Barthel index of the observation group was significantly higher than that of the control group (P 0.05). Conclusions Combined treatment of edaravone, clopidogrel and butylphthalide in jection in patients with acute progressive cerebral infarction can improve the daily activities of patients, reduce nerve damage, and regulate levels of serum S-100β protein, NSE, IL-1, IL-2, IL-6 and other indicators, which has a good application effect. Key words: Edaravone; Butylphthalide; Clopidogrel; Acute cerebral infarction